Skip to main content
Board-Certified Psychiatrist (ABPN)U.S. + Israel LicensedTelepsychiatry since 2013Psychiatrist present during every IM sessionPrescription treatment · Ages 18+ · Medical evaluation required

Desktop Recommended for Best Experience

For the best experience completing forms, assessments, and navigating patient resources, we recommend using a desktop or laptop computer.

This site is informational. Treatment requires full medical evaluation. Not for emergencies — if in crisis, contact local emergency services or a crisis line.
Visual Neuroscience Library · Episode 7

Glutamate → AMPA → BDNF: A Conceptual Pathway

The Molecular Cascade Behind Ketamine's Plasticity-Promoting Effects

2 min

Researchers have proposed a simplified molecular pathway to help explain how a single ketamine dose may rapidly promote neural plasticity. In this model, ketamine blocks NMDA receptors, shifting glutamate signaling in a way that boosts AMPA receptor activity. This is thought to trigger the release of BDNF — a growth factor that supports the growth and strengthening of synaptic connections. This cascade is one of several frameworks scientists use to understand ketamine's effects; it is conceptual and simplified, not a complete picture.

What is reasonably well supported

• Ketamine blocks NMDA-type glutamate receptors, which is its best-characterized pharmacological action. • Increased AMPA receptor signaling and downstream release of BDNF are documented in preclinical models following ketamine. • BDNF supports synaptogenesis (the formation of new synaptic connections), including in the prefrontal cortex. • The glutamate–AMPA–BDNF cascade is a widely cited framework in the ketamine antidepressant literature.

What remains uncertain

• Whether this single pathway fully accounts for ketamine's clinical effects, which likely involve multiple mechanisms. • How directly the molecular cascade in animal models translates to human therapeutic outcomes. • The relative contribution of ketamine's metabolites (e.g., hydroxynorketamine) to plasticity. • Whether BDNF levels measured in blood reliably reflect the brain changes relevant to treatment response.

Clinical framing

The glutamate–AMPA–BDNF pathway offers a useful story for understanding why ketamine may promote plasticity, but it is a simplification. Ketamine should not be presented as "boosting BDNF," "growing new brain cells," or "rebuilding the brain." Clinically, the value of this framework is that it underscores ketamine as a potential opener of a plasticity window — one that therapeutic work and integration can help translate into lasting change.

References and further reading

Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling

Pending review

Cavalleri L, Merlo Pich E, Millan MJ, Chiamulera C, Kunath T, Spano PF, Collo G

Molecular Psychiatry· 2018Reference

Translational cell study using mouse and human iPSC-derived dopaminergic neurons, supporting AMPAR/BDNF/mTOR-linked structural plasticity. Added as supporting evidence; pending clinician review.

View sourceDOI: 10.1038/mp.2017.241

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

Pending review

Yang C, Yang J, Luo A, Hashimoto K

Translational Psychiatry· 2019Review

Mechanistic review emphasizing AMPA, BDNF/TrkB, mTOR/ERK, enantiomer and metabolite complexity; supports presenting the cascade as one model rather than a complete mechanism. Added as supporting evidence; pending clinician review.

View sourcePMID: 31699965; DOI: 10.1038/s41398-019-0624-1

Synaptic dysfunction in depression: potential therapeutic targets

Verified

Duman RS, Aghajanian GK

Science· 2012Review

Landmark review (Science, 2012;338:68-72) describing the glutamate–AMPA–BDNF–synaptic plasticity cascade thought to underlie ketamine's antidepressant effects. Verified via PubMed.

View sourcePMID: 23042884 · DOI: 10.1126/science.1222939

This content is educational and does not constitute medical advice, a treatment recommendation, or a guarantee of outcome. All diagrams and explanations are conceptual and simplified for general understanding. They are not direct representations of individual patient data. Individual suitability for ketamine-assisted psychotherapy requires a screening call and full psychiatric evaluation. Research on ketamine's effects on brain networks is active and evolving.

Want to learn if KAP is right for you?

Start with a free 15–20 minute screening call.

Book Free Screening →